2010  |  2009  |  2008  |  2007  |  2006–2004  |   Download a list of references.

1. The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis.
   Ruiz S, Santos E, Bustelo XR.
   PLoS One. 2009 Dec 14;4(12):e8229. Pubmed
2. P-REX2a driving tumorigenesis by PTEN inhibition.
   Pejovic T, Pande NT, Mori M, Mhawech-Fauceglia P, Harrington C, Mongoue-Tchokote S, Dim D, Andrews C, Beck A, Tarumi Y, Djilas J, Cappuccini F, Caballero O, Huang J, Levy S, Tsiamouri A, Cain J, Bagby GC, Strausberg RL, Simpson AJ, Odunsi KO.
   Sci Signal. 2009 Oct 27;2(94):pe68. Pubmed
3. Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation.
   Ricca TI, Liang G, Suenaga AP, Han SW, Jones PA, Jasiulionis MG.
   Transl Oncol. 2009 Dec;2(4):329-40. Pubmed
4. Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.
   Leslie NR.
   Transl Oncol. 2009 Dec;2(4):341-9. Pubmed
5. Clusterin (CLU) and prostate cancer.
   Rizzi F, Bettuzzi S.
   Adv Cancer Res. 2009;105:1-19. Pubmed
6. Disease gene characterization through large-scale co-expression analysis.
   Day A, Dong J, Funari VA, Harry B, Strom SP, Cohn DH, Nelson SF.
   PLoS One. 2009 Dec 31;4(12):e8491. Pubmed
7. The helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesis.
   Parsyan A, Shahbazian D, Martineau Y, Petroulakis E, Alain T, Larsson O, Mathonnet G, Tettweiler G, Hellen CU, Pestova TV, Svitkin YV, Sonenberg N.
   Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22217-22. Epub 2009 Dec 11. Pubmed
8. Discovering collectively informative descriptors from high-throughput experiments.
   Jeffries CD, Ward WO, Perkins DO, Wright FA.
   BMC Bioinformatics. 2009 Dec 18;10:431. Pubmed
9. Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to control cell polarization, migration, and invasion.
   Hall EH, Daugherty AE, Choi CK, Horwitz AF, Brautigan DL.
   J Biol Chem. 2009 Dec 11;284(50):34713-22. Epub 2009 Oct 13. Pubmed
10. Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.
    Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M, Corti A, Baffa R, Sala A.
    Oncogene 28, 4344–4352 (10 December 2009) | doi:10 1038/onc 2009 286 Pubmed
11. The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts.
    Shaw A, Gipp J, Bushman W.
    Oncogene. 2009 Dec 17;28(50):4480-90. Epub 2009 Sep 28. Pubmed
12. Housekeeping genes in prostate tumorigenesis.
    Byun J, Logothetis CJ, Gorlov IP.
    Int J Cancer. 2009 Dec 1;125(11):2603-8. Pubmed
13. Global repression of cancer gene expression in a zebrafish model of melanoma is linked to epigenetic regulation.
    Anelli V, Santoriello C, Distel M, Köster RW, Ciccarelli FD, Mione M.
    Zebrafish. 2009 Dec;6(4):417-24. Pubmed
14. Gene expression profiling of archival tongue squamous cell carcinomas provides sub-classification based on DNA repair genes.
    Rentoft M, Laurell G, Coates PJ, Sjöström B, Nylander K.
    Int J Oncol 2009 Dec;35(6):1321-30 Pubmed
15. Translocations in epithelial cancers.
    Brenner JC, Chinnaiyan AM.
    Biochim Biophys Acta 2009 Dec;1796(2):201-15 Epub 2009 May 4 Pubmed
16. CRX is a diagnostic marker of retinal and pineal lineage tumors.
    Santagata S, Maire CL, Idbaih A, Geffers L, Correll M, Holton K, Quackenbush J, Ligon KL.
    PLoS One. 2009 Nov 20;4(11):e7932. Pubmed
17. Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis.
    Unoki M, Brunet J, Mousli M.
    Biochem Pharmacol. 2009 Nov 15;78(10):1279-88. Epub 2009 Jun 6. Pubmed
18. Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex.
    Moscat J, Diaz-Meco MT, Wooten MW.
    Cell Death Differ. 2009 Nov;16(11):1426-37. Epub 2009 Aug 28. Pubmed
19. Cross-platform method for identifying candidate network biomarkers for prostate cancer.
    Jin G, Zhou X, Cui K, Zhang XS, Chen L, Wong ST.
    IET Syst Biol. 2009 Nov;3(6):505-12. Pubmed
20. Necdin: a multi functional protein with potential tumor suppressor role?
    Chapman EJ, Knowles MA.
    Mol Carcinog. 2009 Nov;48(11):975-81. Pubmed
21. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer.
    Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM.
    Nat Biotechnol. 2009 Nov;27(11):1005-11. Epub 2009 Nov 1. Pubmed
22. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion.
    Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS.
    Mol Cancer Res. 2009 Nov;7(11):1756-70. Epub 2009 Nov 3. Pubmed
23. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer.
    Wortham NC, Ahamed E, Nicol SM, Thomas RS, Periyasamy M, Jiang J, Ochocka AM, Shousha S, Huson L, Bray SE, Coombes RC, Ali S, Fuller-Pace FV.
    Oncogene. 2009 Nov 19;28(46):4053-64. Epub 2009 Aug 31. Pubmed
24. Correlating Global Gene Regulation to Angiogenesis in the Developing Chick Extra-Embryonic Vascular System.
    Javerzat S, Franco M, Herbert J, Platonova N, Peille AL, Pantesco V, De Vos J, Assou S, Bicknell R, Bikfalvi A, Hagedorn M.
    PLoS One 2009 Nov 17;4(11):e7856 Pubmed
25. Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation.
    Devlin AH, Thompson P, Robson T, McKeown SR.
    Mol Carcinog 2009 Nov 11 [Epub ahead of print] Pubmed
26. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival.
    Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND.
    Breast Cancer Res 2009 Nov 10;11(6):R81 [Epub ahead of print] Pubmed
27. Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias.
    Tsui IF, Poh CF, Garnis C, Rosin MP, Zhang L, Lam WL.
    Int J Cancer 2009 Nov 1;125(9):2219-28 Pubmed
28. Atypical protein kinase C activity is required for extracellular matrix degradation and invasion by Src-transformed cells.
    Rodriguez EM, Dunham EE, Martin GS.
    J Cell Physiol. 2009 Oct;221(1):171-82. Pubmed
29. Comprehensive Analysis of Conditioned Media from Ovarian Cancer Cell Lines Identifies Novel Candidate Markers of Epithelial Ovarian Cancer.
    Gunawardana CG, Kuk C, Smith CR, Batruch I, Soosaipillai A, Diamandis EP.
    J Proteome Res 2009 Oct;8(10):4705-13 Pubmed
30. Identification of Tumor-associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein Microarrays.
    Babel I, Barderas R, Díaz-Uriarte R, Martínez-Torrecuadrada JL, Sánchez-Carbayo M, Casal JI.
    Mol Cell Proteomics 2009 Oct;8(10):2382-95 Epub 2009 Jul 28 Pubmed
31. HAX-1: A multifunctional protein with emerging roles in human disease.
    Fadeel B, Grzybowska E.
    Biochim Biophys Acta 2009 Oct;1790(10):1139-48 Epub 2009 Jun 12 Pubmed
32. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.
    Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G.
    Nat Struct Mol Biol 2009 Oct;16(10):1086-93 Epub 2009 Sep 27 Pubmed
33. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.
    Montañez-Wiscovich ME, Seachrist DD, Landis MD, Visvader J, Andersen B, Keri RA.
    Oncogene 2009 Oct 15;28(41):3608-18 Epub 2009 Aug 3 Pubmed
34. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
    Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R.
    Blood 2009 Oct 15;114(16):3361-2 Pubmed
35. A Role for the Clock Gene Per1 in Prostate Cancer.
    Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, Koeffler HP.
    Cancer Res 2009 Oct 1;69(19):7619-25 Epub 2009 Sep 14 Pubmed
36. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.
    Yang ZQ, Liu G, Bollig-Fischer A, Haddad R, Tarca AL, Ethier SP.
    Int J Cancer 2009 Oct 1;125(7):1613-21 Pubmed
37. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases.
    Vellaichamy A, Sreekumar A, Strahler JR, Rajendiran T, Yu J, Varambally S, Li Y, Omenn GS, Chinnaiyan AM, Nesvizhskii AI.
    PLoS One. 2009 Sep 18;4(9):e7075. Pubmed
38. Gene networks in Drosophila melanogaster: integrating experimental data to predict gene function.
    Costello JC, Dalkilic MM, Beason SM, Gehlhausen JR, Patwardhan R, Middha S, Eads BD, Andrews JR.
    Genome Biol 2009;10(9):R97 Epub 2009 Sep 16 Pubmed
39. Unraveling the Signal-Transduction Networks in Cancer Metastasis.
    Guangxu Jin, Kemi Cui, Xiaobo Zhou, Wong S. 
    Signal Processing Magazine, IEEE 2009 Sep;26(5):129-132 Link
40. Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective.
    Huang S, Ernberg I, Kauffman S.
    Semin Cell Dev Biol 2009 Sep;20(7):869-76 Epub 2009 Jul 10 Pubmed
41. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.
    Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL.
    J Clin Invest 2009 Sep;119(9):2678-90 doi: 10 1172/JCI37815 Epub 2009 Aug 24 Pubmed
42. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition.
    McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL.
    J Clin Invest 2009 Sep;119(9):2663-77 doi: 10 1172/JCI37691 Epub 2009 Aug 24 Pubmed
43. RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease.
    Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M.
    Neoplasia 2009 Sep;11(9):956-63 Pubmed
44. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.
    Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A.
    Oncogene 2009 Sep 17;28(37):3296-306 Epub 2009 Jul 27 Pubmed
45. The IKK2/NF-kappa B pathway suppresses MYC-induced lymphomagenesis.
    Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T.
    Blood 2009 Sep 17;114(12):2448-58 Epub 2009 Jul 23 Pubmed
46. DNMT1 and DNMT3B Modulate Distinct Polycomb-Mediated Histone Modifications in Colon Cancer.
    Jin B, Yao B, Li JL, Fields CR, Delmas AL, Liu C, Robertson KD.
    Cancer Res 2009 Sep 15;69(18):7412-21 Epub 2009 Sep 1 Pubmed
47. Gene Expression Profile of Primary Prostate Epithelial and Stromal Cells in Response to Sulforaphane or Iberin Exposure.
    Chambers KF, Bacon JR, Kemsley EK, Mills RD, Ball RY, Mithen RF, Traka MH.
    Prostate 2009 Sep 15;69(13):1411-21 Pubmed
48. Gene expression profiling of human alveolar macrophages infected by B. anthracis spores demonstrates TNF-alpha and NF-kappa b are key components of the innate immune response to the pathogen.
    Dozmorov M, Wu W, Chakrabarty K, Booth JL, Hurst RE, Coggeshall KM, Metcalf JP.
    BMC Infect Dis 2009 Sep 10;9:152 Pubmed
49. Identification of a Protein, G0S2, That Lacks Bcl-2 Homology Domains and Interacts with and Antagonizes Bcl-2.
    Welch C, Santra MK, El-Assaad W, Zhu X, Huber WE, Keys RA, Teodoro JG, Green MR.
    Cancer Res 2009 Sep 1;69(17):6782-9 Epub 2009 Aug 25 Pubmed
50. Biological determinants of endocrine resistance in breast cancer.
    Musgrove EA, Sutherland RL.
    Nat Rev Cancer. 2009 Sep;9(9):631-43. Pubmed
51. A genomic perspective on vitamin D signaling.
    Carlberg C, Seuter S.
    Anticancer Res. 2009 Sep;29(9):3485-93. Pubmed
52. Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System.
    Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R.
    Cancer Prev Res (Phila Pa) 2009 Aug;2(8):702-11 Epub 2009 Jul 28 Pubmed
53. Transcriptional activation of the Lats1 tumor suppressor gene in tumors of CUX1 transgenic mice.
    Siam R, Harada R, Cadieux C, Battat R, Vadnais C, Nepveu A.
    Mol Cancer 2009 Aug 5;8:60 Pubmed
54. Tumor Suppression by Phospholipase C-beta 3 via SHP-1-Mediated Dephosphorylation of Stat5.
    Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T.
    Cancer Cell 2009 Aug 4;16(2):161-71 Pubmed
55. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data.
    Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ.
    BMC Med Genomics. 2009 Aug 4;2:48. Pubmed
56. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
    Huang J, Wu S, Wu CL, Manning BD.
    Cancer Res. 2009 Aug 1;69(15):6107-14. Epub 2009 Jul 14. Pubmed
57. Proteomic approaches in neuroblastoma: a complementary clinical platform for the future.
    Kumar HR, Zhong X, Rescorla FJ, Hickey RJ, Malkas LH, Sandoval JA.
    Expert Rev Proteomics. 2009 Aug;6(4):387-94. Pubmed
58. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer.
    Zha J, O'Brien C, Savage H, Huw LY, Zhong F, Berry L, Lewis Phillips GD, Luis E, Cavet G, Hu X, Amler LC, Lackner MR.
    Mol Cancer Ther. 2009 Aug;8(8):2110-21. Epub 2009 Aug 11. Pubmed
59. Oncomine meta-analysis of breast cancer microarray data identifies upregulation of NRF-1 expression in human breast carcinoma.
    Kunkle, B., Q. Felty, F. Trevino, D. Roy
    18th World IMACS / MODSIM Congress, Cairns, Australia 13-17 July 2009
60. A c-Myc regulatory subnetwork from human transposable element sequences.
    Wang J, Bowen NJ, Chang L, Mariño-Ramírez H, Jordan IK.
    Mol Biosyst 2009 Jul 21 [Epub ahead of print] Pubmed
61. Computational Identification of a p38(SAPK)-Regulated Transcription Factor Network Required for Tumor Cell Quiescence.
    Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, Kourtidis A, Conklin DS, Aguirre-Ghiso JA.
    Cancer Res 2009 Jul 15;69(14):5664-72 Epub 2009 Jul 7 Pubmed
62. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer.
    DiMeo TA, Anderson K, Phadke P, Feng C, Perou CM, Naber S, Kuperwasser C.
    Cancer Res. 2009 Jul 1;69(13):5364-73. Epub 2009 Jun 23. Pubmed
63. Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes.
    Zhang M, Zhang L, Zou J, Yao C, Xiao H, Liu Q, Wang J, Wang D, Wang C, Guo Z.
    Bioinformatics. 2009 Jul 1;25(13):1662-8. Epub 2009 May 5. Pubmed
64. Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment.
    van Vuurden DG, Yazdani M, Bosma I, Broekhuizen AJ, Postma TJ, Heimans JJ, van der Valk P, Aronica E, Tannous BA, Würdinger T, Kaspers GJ, Cloos J.
    PLoS One. 2009 Jun 18;4(6):e5953. Pubmed
65. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis.
    Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM.
    Cancer Res. 2009 Jun 15;69(12):5168-76. Epub 2009 Jun 2. Pubmed
66. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
    Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA.
    Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9435-40. Epub 2009 May 28. Pubmed
67. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha.
    Akaogi K, Nakajima Y, Ito I, Kawasaki S, Oie SH, Murayama A, Kimura K, Yanagisawa J.
    Oncogene. 2009 Jun 8. [Epub ahead of print] Pubmed
68. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.
    Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J.
    BMC Cancer. 2009 Jun 7;9:173. Pubmed
69. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors.
    Hussain S, Zhang Y, Galardy PJ.
    Cell Cycle. 2009 Jun 1;8(11):1688-97. Pubmed
70. Rab7 activation by growth factor withdrawal contributes to the induction of apoptosis.
    Romero Rosales K, Peralta ER, Guenther GG, Wong SY, Edinger AL.
    Mol Biol Cell. 2009 Jun;20(12):2831-40. Epub 2009 Apr 22. Pubmed
71. Sam-pointed domain containing Ets transcription factor in luminal breast cancer pathogenesis.
    Sood AK, Wang J, Mhawech-Fauceglia P, Jana B, Liang P, Geradts J.
    Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1899-903. Pubmed
72. Heterochromatin protein 1alpha: a hallmark of cell proliferation relevant to clinical oncology.
    De Koning L, Savignoni A, Boumendil C, Rehman H, Asselain B, Sastre-Garau X, Almouzni G.
    EMBO Mol Med. 2009 Jun;1(3):178-91. Pubmed
73. HtrA serine proteases as potential therapeutic targets in cancer.
    Chien J, Campioni M, Shridhar V, Baldi A.
    Curr Cancer Drug Targets. 2009 Jun;9(4):451-68. Pubmed
74. Selenoprotein P regulation by the glucocorticoid receptor.
    Rock C, Moos PJ.
    Biometals 2009 Jun 10 [Epub ahead of print] Pubmed
75. Embryonic stem cell markers expression in cancers.
    Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B.
    Biochem Biophys Res Commun. 2009 May 29;383(2):157-62. Epub 2009 Mar 4. Pubmed
76. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.
    Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Huang W, Largaespada DA, Marker PC.
    Cancer Res. 2009 May 15;69(10):4388-97. Epub 2009 Apr 28. Pubmed
77. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
    Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA.
    Clin Cancer Res. 2009 May 15;15(10):3406-15. Epub 2009 Apr 28. Pubmed
78. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.
    Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A.
    J Natl Cancer Inst. 2009 May 6;101(9):663-77. Epub 2009 Apr 28. Pubmed
79. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells.
    Mannefeld M, Klassen E, Gaubatz S.
    Cancer Res. 2009 May 1;69(9):4073-80. Epub 2009 Apr 21. Pubmed
80. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer.
    Wang R, Morris DS, Tomlins SA, Lonigro RJ, Tsodikov A, Mehra R, Giordano TJ, Kunju LP, Lee CT, Weizer AZ, Chinnaiyan AM.
    Cancer Res. 2009 May 1;69(9):3810-8. Epub 2009 Apr 21. Pubmed
81. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
    Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM.
    Prostate. 2009 May 1;69(6):603-9. Pubmed
82. Proepithelin is an autocrine growth factor for bladder cancer.
    Lovat F, Bitto A, Xu SQ, Fassan M, Goldoni S, Metalli D, Wubah V, McCue P, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A.
    Carcinogenesis. 2009 May;30(5):861-8. Epub 2009 Feb 23. Pubmed
83. Artemin is oncogenic for human mammary carcinoma cells.
    Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, Wu ZS, Zhu T, Liu DX, Lobie PE.
    Oncogene. 2009 May 14;28(19):2034-45. Epub 2009 Apr 13. Pubmed
84. Quantitative proteomic analysis of follicular lymphoma cells in response to rituximab.
    Everton KL, Abbott DR, Crockett DK, Elenitoba-Johnson KS, Lim MS.
    J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1;877(13):1335-43. Epub 2008 Oct 28. Pubmed
85. A compendium of potential biomarkers of pancreatic cancer.
    Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A.
    PLoS Med. 2009 Apr 7;6(4):e1000046. Epub 2009 Apr 7. Pubmed
86. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.
    Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Chen H, Kong X, Melamed J, Fang S, Xiao Z, Veenstra TD, Qiu Y.
    Cancer Cell. 2009 Apr 7;15(4):270-82. Pubmed
87. Learning therapeutic lessons from metastasis suppressor proteins.
    Smith SC, Theodorescu D.
    Nat Rev Cancer. 2009 Apr;9(4):253-64. Epub 2009 Feb 26. Pubmed
88. Protein kinase C intervention: the state of play.
    Roffey J, Rosse C, Linch M, Hibbert A, McDonald NQ, Parker PJ.
    Curr Opin Cell Biol. 2009 Apr;21(2):268-79. Epub 2009 Feb 23. Pubmed
89. Early gene expression changes during embryonic stem cell differentiation into cardiomyocytes and their modulation by monobutyl phthalate.
    van Dartel DA, Pennings JL, Hendriksen PJ, van Schooten FJ, Piersma AH.
    Reprod Toxicol. 2009 Apr;27(2):93-102. Epub 2008 Dec 31. Pubmed
90. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer.
    Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA.
    Science. 2009 Mar 27;323(5922):1747-50. Epub 2009 Feb 26. Pubmed
91. APRIL is overexpressed in cancer: link with tumor progression.
    Moreaux J, Veyrune JL, De Vos J, Klein B.
    BMC Cancer. 2009 Mar 16;9:83. Pubmed
92. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation.
    Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A.
    Clin Cancer Res. 2009 Mar 15;15(6):2058-66. Epub 2009 Feb 24. Pubmed
93. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
    Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ.
    PLoS One. 2009;4(3):e4710. Epub 2009 Mar 9. Pubmed
94. Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth.
    Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, Goldoni S, Fassan M, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A.
    Am J Pathol. 2009 Mar;174(3):1037-47. Epub 2009 Jan 29. Pubmed
95. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors.
    Ojalvo LS, King W, Cox D, Pollard JW.
    Am J Pathol. 2009 Mar;174(3):1048-64. Epub 2009 Feb 13. Pubmed
96. Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation.
    Billottet, C; Banerjee, L; Vanhaesebroeck, B; Khwaja, A
    Cancer Res. 2009 Feb 1;69(3):1027-36. Epub 2009 Jan 27. Pubmed
97. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
    Arencibia, JM; Martin, S; Perez-Rodriguez, FJ; Bonnin, A
    Int J Oncol. 2009 Feb;34(2):457-63. Pubmed
98. Oncogenic gene fusions in epithelial carcinomas.
    Prensner JR, Chinnaiyan AM.
    Curr Opin Genet Dev. 2009 Feb;19(1):82-91. Epub 2009 Feb 21. Pubmed
99. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours.
    Sun R, Fu X, Li Y, Xie Y, Mao Y.
    BMC Genomics. 2009 Feb 26;10:93. Pubmed
100. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.
     Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM.
     Nature. 2009 Feb 12;457(7231):910-4. Pubmed
101. Characterization of EVL-I as a protein kinase D substrate.
     Janssens, K; De Kimpe, L; Balsamo, M; Vandoninck, S; Vandenheede, JR; Gertler, F; Van Lint, J
     Cell Signal. 2009 Feb;21(2):282-92. Epub 2008 Oct 29. Pubmed
102. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2.
     Gordon KJ, Kirkbride KC, How T, Blobe GC.
     Carcinogenesis. 2009 Feb;30(2):238-48. Epub 2008 Dec 4. Pubmed
103. The Ral GTPase pathway in metastatic bladder cancer: Key mediator and therapeutic target.
     Smith, SC; Theodorescu, D
     Urol Oncol. 2009 Jan-Feb;27(1):42-7. Pubmed
104. Modulated expression of WFDC1 during carcinogenesis and cellular senescence.
     Madar, S; Brosh, R; Buganim, Y; Ezra, O; Goldstein, I; Solomon, H; Kogan, I; Goldfinger, N; Klocker, H; Rotter, V
     Carcinogenesis. 2009 Jan;30(1):20-7. Epub 2008 Oct 8. Pubmed
105. DEK Proto-Oncogene Expression Interferes with the Normal Epithelial Differentiation Program.
     Wise-Draper, TM; Morreale, RJ; Morris, TA; Mintz-Cole, RA; Hoskii, EE; Balsitis, SJ; Husseinzadeh, N; Witte, DP; Wikenheiser-Brokamp, KA; Lambert, PF; Wells, SI
     Am J Pathol. 2009 Jan;174(1):71-81. Epub 2008 Nov 26. Pubmed
106. AFAP120 regulates actin organization during neuronal differentiation.
     Xu X, Harder J, Flynn DC, Lanier LM.
     Differentiation. 2009 Jan;77(1):38-47. Epub 2008 Oct 16. Pubmed
107. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo.
     Galvez AS, Duran A, Linares JF, Pathrose P, Castilla EA, Abu-Baker S, Leitges M, Diaz-Meco MT, Moscat J.
     Mol Cell Biol. 2009 Jan;29(1):104-15. Epub 2008 Oct 27. Pubmed
108. Key signalling nodes in mammary gland development and cancer: Myc.
     Hynes NE, Stoelzle T.
     Breast Cancer Res. 2009;11(5):210. Pubmed